XUANZHUBIO-B(02575),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02575 XUANZHUBIO-B

Trading 09-21 14:57:59

9.350

+0.095

+1.03%

High9.695	Low9.125	Vol2.88M
Open9.255	D1 Closing9.255	Amplitude6.16%
Mkt Cap4.84B	Tradable Cap4.84B	Total Shares518.00M
T/O27.40M	T/O Rate0.56%	Tradable Shares517.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":9.35,"timestamp":1789973808462,"preClose":9.255,"halted":0,"volume":2881000,"delay":0,"changeRate":0.010264721772015003,"floatShares":517947790,"shares":518000000,"eps":-0.6211067438649346,"marketStatus":"Trading","change":0.095,"latestTime":"09-21 14:57:59","open":9.255,"high":9.695,"low":9.125,"amount":27398877,"amplitude":0.061588,"askPrice":9.355,"askSize":3000,"bidPrice":9.35,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.4935513409668613,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789978200000},"marketStatusCode":2,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":9.255,"openAndCloseTimeList":[[1789954200000,1789963200000],[1789966800000,1789977600000]],"volumeRatio":0.635068,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575/wiki","defaultTab":"wiki","newsList":[{"id":"1132254404","title":"Xuanzhu Biopharmaceutical Reports Unusual H-Share Price Surge; Preliminary Acquisition Talks Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=1132254404","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132254404?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:21","pubTimestamp":1789647687,"startTime":"0","endTime":"0","summary":"On 17 September 2026, Xuanzhu Biopharmaceutical Co., Ltd. issued a voluntary announcement noting a sharp increase in its H-share price during the current trading session. After conducting what it...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192559481","title":"港股市场分析：美联储加息靴子落地 AI制药板块迎来多重利好催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1192559481","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192559481?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:01","pubTimestamp":1789646502,"startTime":"0","endTime":"0","summary":"美联储时隔三年重启加息周期，以12比0的全票结果将基准利率上调25个基点至3.75%-4%区间。这一常规操作旨在平息债市压力，这也是当前的头号任务，特朗普方面也不得不接受这一现实。利率点阵图显示，今年内可能还有一次加息动作。至于这是否标志着新一轮加息周期的起点，目前下定论为时尚早，关键变量在于油价走势，而这很大程度上取决于特朗普的政策取向。市场对加息已有充分预期，美股跌幅有限，港股仅微跌0.44%...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZTmain","NEMD","VEXC","EMPB","BIL","BBLB","VTHR","BK1141","BK1124","IEI","XLRI","VOO","SMAX","EBUF","KRX","HK0000320264.USD","SPYB","HYGD","SPUU","SKRE","MINT","BK4534","KRE","BOND","IAT","UBT","TFJL","BOXX","FAZ","BK4559","VCSH","ZROZ","HYGU","HIBL","RAUS","XLF","VGSH","BK1553","SH","BBIB","MYCN","UPRO","AGIX","VFH","BK4588","TSYW","CHAT","SPXL","IEF","HK0000320223.HKD","BK1191","AIPO","BK1212","TBJL","IVV","SPXU","VGLT","FLGV","FEM","NGHT","LQD","JULD","TNmain","SPY","HK0000306701.USD","BK4535","SPXS","BK1574","YSPY","01548","EIM","OOQB","HYG","SPYI","TLTX","MUNX","VGIT","07618","TLH","BSV","ZFmain","BK4585","SHY","HAWG","LIAJ","LQDD","TBIL","SPYM","UDN","BK4550","01117","JPST","SCHO","BBSB","BK1583","MUB","QTOC","SGOV",".SPX","VXUS","TIP","TYO","IGOV","BWX","SHV","BWZ","EDV","MMAX","LQDU","BND","USHY","SG9999014674.SGD","HMOP","BK1242","ARTY","KBE","SPYU","02575","SPDN","DPST","NELS","BK4504","TLTW","UBmain","01477","TMF","ESmain","BK1589","BK4581","OEF","DBND","MESmain","UUP","PBDC","SSO","TLT","KBWB","GOVT","TLTI","TBT","XBIL","SPYH","WAMA","SDS","GOLY","BK4561","06969","BK1580","DMAX","ISHG","AGG","GBIL","SPYQ","VCIT","BK1576","KCAI","ZBmain","HK0000306685.HKD","CIVG","OEX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165620914","title":"XUANZHUBIO-B Shares Surge as Preliminary Acquisition Talks Surface","url":"https://stock-news.laohu8.com/highlight/detail?id=1165620914","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165620914?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:52","pubTimestamp":1789645934,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (HKG: 02575) saw its H-share price climb during Wednesday's trading session, prompting the company to release a statement addressing the market movement.The board of XUANZHUBIO-B said it...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668961716","title":"Xuanzhu Biopharmaceutical Co - no Assurance Potential Acquisition Will Materialize or be Consummated","url":"https://stock-news.laohu8.com/highlight/detail?id=2668961716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668961716?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:44","pubTimestamp":1789645471,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nFWN4590C9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668961715","title":"Xuanzhu Biopharmaceutical Co Ltd - as of Sept 17 Negotiations are Still Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2668961715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668961715?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:44","pubTimestamp":1789645471,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nFWN4590C9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668796179","title":"Xuanzhu Biopharmaceutical - Currently in Preliminary Discussions with Certain Party Regarding a Potential Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2668796179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668796179?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:44","pubTimestamp":1789645471,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nFWN4590C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118563132","title":"Hong Kong Stocks in Focus: Xuanzhu Bio-B (02575) Jumps Over 40% After Signing Tripartite Commercial Agreement in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=1118563132","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118563132?lang=en_us&edition=fundamental","pubTime":"2026-09-17 13:48","pubTimestamp":1789624097,"startTime":"0","endTime":"0","summary":"Shares of Xuanzhu Bio-B (02575) surged more than 40% during the afternoon trading session on Wednesday, last up 34.69% at HK$10.95 with turnover reaching HK$92.89 million.The rally comes after the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK4588","VXUS","BK1191","BK4585","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140600787","title":"Xuanzhu Biopharma Interim 2026: Revenue Jumps 288.10%, Net Loss Contracts 32.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140600787","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140600787?lang=en_us&edition=fundamental","pubTime":"2026-09-16 17:18","pubTimestamp":1789550286,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. released its unaudited interim results for the six months ended 30 June 2026. Revenue rose to RMB 69.44 million, an increase of 288.10% year-on-year, driven by...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Xuanzhu Biopharma Interim 2026: Revenue Jumps 288.10%, Net Loss Contracts 32.10%","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128134753","title":"Xuanzhu Biopharmaceutical Keeps Share Base Unchanged in August 2026 and Meets Public-Float Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=1128134753","media":"Bulletin Express","labels":["SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128134753?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:43","pubTimestamp":1788522238,"startTime":"0","endTime":"0","summary":"For the month ended 31 August 2026, Xuanzhu Biopharmaceutical Co., Ltd. reported no changes in its share capital structure. Issued H-shares remained at 517.95 million, each with a par value of RMB 1,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167309370","title":"Xuanzhu Biopharm seals exclusive Thailand deal with Innobic for Bireociclib commercialisation through 2036","url":"https://stock-news.laohu8.com/highlight/detail?id=1167309370","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167309370?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:25","pubTimestamp":1788427515,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharm; stock name: XUANZHUBIO-B) has entered into a tri-party commercial agreement with Thailand-based Innobic (Asia) Co., Ltd. and Hong...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878574","title":"Sihuan Pharma Affiliate Xuanzhu Biopharm Grants Innobic Exclusive Thailand Commercialization Rights for Bireociclib Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878574","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664878574?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:18","pubTimestamp":1788427127,"startTime":"0","endTime":"0","summary":"Sihuan Pharma affiliate Xuanzhu Biopharm grants Innobic exclusive Thailand commercialization rights for Bireociclib tabletsSihuan Pharmaceutical’s non-wholly owned unit Xuanzhu Biopharm granted exclus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL8K9jwT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","00460","BK1515","02575","BK1191","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109166923","title":"XUANZHUBIO-B Partners with INNOBIC to Commercialize Pyrotinib in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=1109166923","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109166923?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:18","pubTimestamp":1788427123,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) has announced a tripartite commercial agreement with Thai pharmaceutical firm Innobic (Asia) Co., Ltd. and ZaoAn International Trading Co., Ltd. for its pyrotinib tablets, valid...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664878348","title":"Xuanzhu Biopharmaceutical Co - Announces Commercial Cooperation with Innobic for Birecociclib in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2664878348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664878348?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:13","pubTimestamp":1788426788,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U1D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487831","title":"Xuanzhu Biopharmaceutical Co - Grants Exclusive Commercialisation Rights for Birecociclib in Thailand to Innobic (Asia) and Zaoan International","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487831","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664487831?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:13","pubTimestamp":1788426788,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U1D6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123959722","title":"Hong Kong Stock Market Pulse | XUANZHUBIO-B (02575) Surges Over 5% Pre-Noon as H1 Revenue Jumps 288.1% on Dual Licensing and In-Licensing Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1123959722","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123959722?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:42","pubTimestamp":1788406936,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) saw its shares climb more than 5% during the morning trading session, last up 5.42% at HK$9.915, with turnover reaching HK$2.7797 million.The company released its interim results...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK4588","VXUS","BK1191","BK4585","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662726707","title":"Xuanzhu Biopharmaceutical (SEHK:2575) Stock Still Carries A Lofty P S Burden","url":"https://stock-news.laohu8.com/highlight/detail?id=2662726707","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662726707?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:25","pubTimestamp":1787829933,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical stock has been under pressure, with the share price down about 5% over the past week and more than 35% over three months. Yet the latest half year results tell a more nuanced story. Revenue for H1 2026 reached ¥69.441 million and the loss narrowed to ¥75.34 million, which softened basic earnings per share to a loss of ¥0.15.\nThe real flashpoint for sentiment is valuation. Xuanzhu trades on a P/S ratio of 45.4x, which is far above the Hong Kong pharmaceuticals...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/xuanzhu-biopharmaceutical-sehk2575-stock-still-carries-a-lof","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/xuanzhu-biopharmaceutical-sehk2575-stock-still-carries-a-lof","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154655464","title":"Morning Market Wrap: Hong Kong Shares Rise 0.68% as Copper Stocks Take the Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=1154655464","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154655464?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:07","pubTimestamp":1787717221,"startTime":"0","endTime":"0","summary":"Hong Kong's benchmark index kicked off the morning session with a 0.68% gain, advancing 174 points to reach 25,685 points, while the tech-heavy Hang Seng Tech Index climbed a more robust 1.58%....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","IE00BZ08YT58.USD","LU0605514214.HKD","LU2039709279.SGD","IE0008369823.USD","LU1720050803.USD","IE00BVYPNQ40.USD","LU1880383440.USD","03032","LU2213484517.USD","BK1515","LU2125910500.SGD","600362","03908","LU2929501877.USD","06969","07226","IE00BVYPNP33.GBP","603083","BK1516","LU0348767384.USD","LU0594300179.USD","LU1794554557.SGD","06099","IE0031814852.USD","BK1553","IE00BGHQDM52.EUR","01828","HSTECH","LU0463099449.HKD","09088","LU0890818403.SGD","LU0540923850.HKD","LU0359202008.SGD","03993","LU0417516738.SGD","83115","LU2476274308.USD","SG9999004311.SGD","03033","BK1147","LU0149534421.HKD","LU1328277881.USD","LU2778985437.USD","LU0348783233.USD","LU1102505929.USD","02575","LU0359201612.USD","06185","09067","LU0149721374.USD","07300","LU0164880469.USD","07500","LU1102505762.USD","02800","02837","BK1227","BK1592","IE00BYV24P56.USD","02313","LU0348784397.USD","LU0348766576.USD","LU2488822045.USD","03067","IE00BMCWC346.EUR","03423","IE00BZ08YR35.GBP","LU0634319403.HKD","BK1521","LU0348827113.USD","LU0181495838.USD","LU2476274720.SGD","603993","BK1161","IE00BPRC5H50.USD","KURE","LU0140636845.USD","LU0417516571.SGD","SG9999002950.SGD","01112","HK0000286598.CNH","513600","06166","BK1564","00358","03037","03419","SG9999004220.SGD","MCHmain","LU0244354667.USD","BK1568","LU0561508036.HKD","LU1481107354.HKD","06831","09115","BK1190","BK1206","688185","LU0405327494.USD","LU0828237940.HKD","BK1580","IE00B543WZ88.USD","HSI","82800","LU1048596156.SGD","LU0320764599.SGD","LU0359201885.HKD","LU0708995583.HKD","LU0348735423.USD","LU0052750758.USD","09926","LU2187417386.USD","601995","IE00B031J352.USD","IE00B29SXG58.USD","LU1813983027.USD","LU1880383366.USD","BK1240","LU0348825331.USD","LU0417516902.SGD","BK1589","SG9999014674.SGD","SG9999002828.SGD","07552","03088","LU0405327148.USD","LU1961090484.USD","LU0821914370.USD","03417","600999","IE00BZ08YS42.EUR","LU0594300419.USD","LU1831875114.USD","03115","LU0314109678.HKD","BK1501","07200","BK1191","BK1184","IE00B5MMRT66.SGD","BK1149","BK1574","LU1188198961.HKD","IE0008368742.USD","BK1594","BK1242","LU0862451837.USD","IE00B031HY20.USD","02833","LU0650527681.SGD","LU2351347302.SGD","BK1237","01258","BK1233","HTImain","LU0862451753.SGD","LU2399975544.HKD","BK1513","LU2045819591.USD","BK1597","LU0326950275.SGD","LU0607220059.USD","HSImain","HHImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662764154","title":"Xuanzhu Biopharmaceutical: Hy Loss Attributable Rmb75.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662764154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662764154?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:02","pubTimestamp":1787716978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nPLXLQ91WS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662764158","title":"Xuanzhu Biopharmaceutical Co Ltd - ‍Does not Recommend the Payment of an Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2662764158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662764158?lang=en_us&edition=fundamental","pubTime":"2026-08-26 12:02","pubTimestamp":1787716931,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nPLXBQ1N0L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169961354","title":"XUANZHUBIO-B Surges Over 8% Intraday Ahead of Interim Results Release","url":"https://stock-news.laohu8.com/highlight/detail?id=1169961354","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169961354?lang=en_us&edition=fundamental","pubTime":"2026-08-26 10:50","pubTimestamp":1787712647,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) saw its share price climb more than 8% in early trading before paring gains, with the stock last up 5.14% at HK$11.05, recording a turnover of HK$3.64 million. The company has...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":0.0352},{"period":"1month","weight":-0.1831},{"period":"3month","weight":-0.4475},{"period":"6month","weight":-0.7848},{"period":"1year","weight":-0.2022},{"period":"ytd","weight":-0.8687}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":-0.0292},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0208},{"period":"1year","weight":-0.0676},{"period":"ytd","weight":-0.0343}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Xuanzhu Biopharmaceutical Co Ltd is a China-based company principally engaged in biopharmaceutical business. The Company is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The Company mainly conducts its businesses in the domestic market.","exchange":"SEHK","name":"XUANZHUBIO-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XUANZHUBIO-B(02575),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest XUANZHUBIO-B(02575) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"XUANZHUBIO-B,02575,XUANZHUBIO-B股票,XUANZHUBIO-B股票老虎,XUANZHUBIO-B股票老虎国际,XUANZHUBIO-B行情,XUANZHUBIO-B股票行情,XUANZHUBIO-B股价,XUANZHUBIO-B股市,XUANZHUBIO-B股票价格,XUANZHUBIO-B股票交易,XUANZHUBIO-B股票购买,XUANZHUBIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XUANZHUBIO-B(02575),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest XUANZHUBIO-B(02575) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}